Network Point-of-Care Glucose Testing Market is Anticipated to Grow US$ 5.6 Bn By 2030

According to the Vision Research Reports, the Global Network Point-of-Care Glucose Testing market size was valued at USD 3.3 billion in 2020 and is projected to reach US$ 5.6 billion by 2030, growing at a CAGR of 5.10% from 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38458

Growth Factors

Increasing demand for safe and accurate remote patient monitoring options and the need for data-based treatment regimens are major factors driving the market. The integration of advanced technologies including Bluetooth Low Energy (BLE) and Infrared is expected to fuel the market growth in the upcoming years.

Expanding patient base in Asia Pacific and the Middle East and the high demand for advanced diabetes management systems are creating significant growth opportunities in these regions. These regions also include some of the highly preferred destinations for medical tourism. Increasing demand for world-class healthcare services and rising adoption of advanced technology are some of the factors boosting the market growth in these regions. 

Report Highlights

 The Accu-Chek Inform II held the largest revenue share of over 55.0% in 2020. The Accu-Chek Inform II glucose meter is designed for in-vitro diagnostic applications aiding in the determination of blood glucose levels. This glucose meter monitors blood glucose levels in capillary, venous, neonatal and arterial, and whole blood samples. Healthcare professionals adopt Accu-Chek Inform II as it serves as a bedside system that aids in the measurement of glucose and automates the management of data generated by blood glucose tests.

i-STAT is expected to expand at a CAGR of 8.2% over the forecast period. i-STAT portable clinical analyzer developed by Abbott is one of the POC analyzers used at patients’ bedside for critical care tests for electrolytes, coagulation, blood gases, and metabolites. The device is equipped with a number of testing cartridges for monitoring different sets of analytes, which eliminates the need for several analyzers for different analytes.

North America dominated the market in 2020 with a revenue share of over 45.0%. The presence of key market players such as Abbott, Nova Biomedical, and Prodigy Diabetes Care, LLC is one of the major factors contributing to the regional market growth. This has increased the availability of glucose testing products, thereby contributing to revenue generation. In addition, favorable reimbursement policies aid in the rapid adoption of advanced products.

Key Players

  • F. Hoffmann-La Roche Ltd.
  •  Abbott
  • Nova Biomedical
  • Bayer AG/Ascensia diabetes care holdings AG
  • Danaher
Report Coverage Details
Market Size US$ 5.6 billion by 2030
Growth Rate CAGR of 5.10% From 2021 to 2030
Base Year 2020
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered Product
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned F. Hoffmann-La Roche Ltd.; Abbott; Nova Biomedical; Bayer AG/Ascensia Diabetes Care Holdings AG; Danaher

Market Segmentation

  • Product
    • i-STAT
    • Accu-Chek Inform II
    • StatStrip
    • HemoCue
    • CareSens Expert Plus
    • BAROzen H Expert Plus
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
    • Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Thailand
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38458

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Network Point-of-Care Glucose Testing Market, By Product

7.1.  Network Point-of-Care Glucose Testing Market, by Product, 2020-2030

7.1.1.    i-STAT

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Accu-Chek Inform II

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    StatStrip

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    HemoCue

7.1.4.1.        Market Revenue and Forecast (2017-2030)

7.1.5.    CareSens Expert Plus

7.1.5.1.        Market Revenue and Forecast (2017-2030)

7.1.6.    BAROzen H Expert Plus

7.1.6.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Network Point-of-Care Glucose Testing Market, Productal Estimates and Trend Forecast

8.1.  North America

8.1.1.    Market Revenue and Forecast, by Product (2017-2030)

8.1.2.    U.S.

8.1.3.    Rest of North America

8.1.3.1.        Market Revenue and Forecast, by Product (2017-2030)

8.2.  Europe

8.2.1.    Market Revenue and Forecast, by Product (2017-2030)

8.2.2.    UK

8.2.2.1.        Market Revenue and Forecast, by Product (2017-2030)

8.2.3.    France

8.2.3.1.        Market Revenue and Forecast, by Product (2017-2030)

8.2.4.    Rest of Europe

8.2.4.1.        Market Revenue and Forecast, by Product (2017-2030)

8.3.  APAC

8.3.1.    Market Revenue and Forecast, by Product (2017-2030)

8.3.2.    India

8.3.2.1.        Market Revenue and Forecast, by Product (2017-2030)

8.3.3.    China

8.3.3.1.        Market Revenue and Forecast, by Product (2017-2030)

8.3.4.    Japan

8.3.4.1.        Market Revenue and Forecast, by Product (2017-2030)

8.3.5.    Rest of APAC

8.3.5.1.        Market Revenue and Forecast, by Product (2017-2030)

8.4.  MEA

8.4.1.    Market Revenue and Forecast, by Product (2017-2030)

8.4.2.    GCC

8.4.2.1.        Market Revenue and Forecast, by Product (2017-2030)

8.4.3.    North Africa

8.4.3.1.        Market Revenue and Forecast, by Product (2017-2030)

8.4.4.    South Africa

8.4.4.1.        Market Revenue and Forecast, by Product (2017-2030)

8.4.5.    Rest of MEA

8.4.5.1.        Market Revenue and Forecast, by Product (2017-2030)

8.5.  Latin America

8.5.1.    Market Revenue and Forecast, by Product (2017-2030)

8.5.2.    Brazil

8.5.2.1.        Market Revenue and Forecast, by Product (2017-2030)

8.5.3.    Rest of LATAM

8.5.3.1.        Market Revenue and Forecast, by Product (2017-2030)

Chapter 9.    Company Profiles

9.1.  F. Hoffmann-La Roche Ltd.

9.1.1.    Company Overview

9.1.2.    Product Offerings

9.1.3.    Financial Performance

9.1.4.    Recent Initiatives

9.2.  Abbott

9.2.1.    Company Overview

9.2.2.    Product Offerings

9.2.3.    Financial Performance

9.2.4.    Recent Initiatives

9.3.  Nova Biomedical

9.3.1.    Company Overview

9.3.2.    Product Offerings

9.3.3.    Financial Performance

9.3.4.    Recent Initiatives

9.4.  Bayer AG/Ascensia diabetes care holdings AG

9.4.1.    Company Overview

9.4.2.    Product Offerings

9.4.3.    Financial Performance

9.4.4.    Recent Initiatives

9.5.  Danaher

9.5.1.    Company Overview

9.5.2.    Product Offerings

9.5.3.    Financial Performance

9.5.4.    Recent Initiatives

Chapter 10.  Research Methodology

10.1.              Primary Research

10.2.              Secondary Research

10.3.              Assumptions

Chapter 11.  Appendix

11.1.              About Us

11.2.              Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38458

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com